Quote: "And what would they base a "Buy" recommendation on???"
My thoughts EXACTLY. "big firms" who give "buy recommendations" (Citi, UBS, Goldman, whoever) don't usually give big ole "buy recommendations" on cash poor, no product, no sales, no "big financing" deal(s), living off of Lincoln dilution "credit line" based companies, not that I'm aware of?
Especially (6 CENT pre R/S split) companies just a few weeks off the OTC who's stock is going nowhere as of right now?
Like the question above states- "buy recommendation" based on what criteria exactly? The common stock has lost about 98% of its value too date- and is sitting where it was at least 3 or 4 yrs ago, unchanged. What's the "buy" part all about exactly?
They got a tiny phase I under their belt right now, very little cash, no phase II even started yet and about 5 yrs minimum (per their Sr Mgt's own words) 5 yrs to a "possible" product and FDA approval and nowhere near enough cash via their present dilution funding line to carry them much past 1 yr, if even that, w/o even providing funding for a large, FDA quality phase 2 trial.
I don't think the big "analyst houses" are exactly all over this one just yet IMO.
